Status:
COMPLETED
An Extension Study for Patients Previously Treated With ARQ 501
Lead Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
Eligibility Criteria
Inclusion
- Signed written informed consent
- Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment
Exclusion
- Have not received previous treatment with ARQ 501 under a treatment protocol
- Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00622063
Start Date
December 1 2006
Last Update
February 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mary Crowley Medical Research Center
Dallas, Texas, United States, 75246